Oncolytics (ONCY) Biotech received a formal letter from the Listing Qualifications Department of The Nasdaq Stock Market dated July 22, informing the company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). The company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker “ONCY.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech Unveils Promising Data on Pelareorep’s Efficacy Across Tumor Types
- Oncolytics reports data from pelareorep studies
- Oncolytics Biotech to Host Webinar on Pelareorep’s Potential in Cancer Treatment
- Oncolytics Biotech’s Strategic Advancements and Leadership Changes Drive Buy Rating
- Oncolytics Biotech Highlights Promising Pelareorep Data in Cancer Treatment